DE
Order
News
Letzte Aktualisierung: January 27, 2022

mRNA vaccine passes phase 1 clinical trials

One of China's mRNA vaccines against Covid is expected to achieve 95 percent efficacy in tests. This was shown by data from the first phase of clinical trials, reports business portal Caixin. The vaccine was jointly developed by Walvax Biotechnology and Suzhou Abogen Biosciences, as well as the Academy of Military Sciences of the Chinese People's Liberation Army, according to Caixin. It bears the designation Arcov.
Testimonial Random Image
Please use HAN to get access to this article.
Secure your information advantage

Exclusive, highly topical and expert information for your industry: In our Professional Briefings, our more than 60 specialized journalists report from Berlin, Brussels and Beijing.

  • All issues by e-mail
  • Access to the web portal table.media and the archive
  • For the decisive minds from politics, business and science

No payment data. No automatic renewal.

4 Weeks free trail
1/2
Select Professional Briefings

*free of charge even after the trial period has expired

Das Late-Night-Memo für die Hauptstadt: Exclusive Meldungen + Pressebriefing

Jeden Morgen die 100 relevantesten Schlagzeilen aus über 1.000 Quellen

Das Leitmedium für die deutschsprachige China-Berichterstattung

Europäische Regulierungen, EU-Energie- und Klimaschutzpolitik, Industriestrategie und Finanzpolitik

Das unabhängige Briefing für Bildungs-Politik, -Strategie und -Forschung

Klimapolitik anderer Staaten und der Europäischen Union, sowie die ganze Breite der internationalen Klimadebatte

Sicherheitslage und -strategie, Verteidigungspolitik und Beschaffung von Militärtechnologie

Für zukunftsfähiges Wirtschaften: Nachhaltigkeitspolitik und Transformationsstrategien

Wissenschaftspolitik, Forschungsstrategie, Innovationsmanagement und Research Funding

Wirtschaftliche Trends, deutsche und internationale Afrika-Politik und Investitionschancen

Regulierung im Agrar- und Lebensmittelsektor auf nationaler und europäischer Ebene

With a focus on the German government and EU Commission, global corporations and medium-sized companies

European regulation, EU climate and environmental policy and innovation to trade and finance

Information during the global hot season - with in-depth analyses on all aspects of the global transformation

Nextback
2/2
How may we address you?
back

Your registration was successful.

Welcome to Table.Media.
You will receive an email with a confirmation link.
Please click on this link to complete your registration.

You have not received an email?


  • Please check your spam folder.
  • Maybe you have registered with a different email address?
  • Please check if you have misspelled your email address.
Mehr zum Thema
Social Media
Be our guest at Table.Media.

Test now for free, without automatic renewal.

Register for free